Vivek Subbiah, MD's Avatar

Vivek Subbiah, MD

@viveksubbiah.bsky.social

Early Phase Drug Development; Oncologist; Precision Medicine; Phase 1 trials; AI & Precision Oncology; Clinical trials. Posts=My own

2,842 Followers  |  294 Following  |  48 Posts  |  Joined: 10.11.2024  |  2.3278

Latest posts by viveksubbiah.bsky.social on Bluesky

Preview
Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - OncoDaily Vivek Subbiah: Impact of FDA Project Optimus Guidance on Early-Phase Trial Design / cancer, David Spigel, Deepak Bhamidipati, Gerald Falchook, Howard Burris,

Impact of FDA Project Optimus Guidance on Early-Phase Trial Design - Vivek Subbiah

@viveksubbiah.bsky.social @fda.gov

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

29.09.2025 21:33 โ€” ๐Ÿ‘ 3    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - OncoDaily Vivek Subbiah: Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series / cancer, International Cancer Patient Coalition,

Honored to Join Global Colleagues and Deliver the Message at the UN for The Last Mile Series - Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

24.09.2025 15:03 โ€” ๐Ÿ‘ 5    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
When AI rejects your grant proposal: algorithms are helping to make funding decisions A Spanish foundation using an artificial-intelligence tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say itโ€™s a breakdown in trust.

โญ๏ธWhen AI rejects your grant proposal: algorithms are helping to make funding decisions
A foundation using an AI tool to screen grant applications says it makes the peer-review process more efficient, but other researchers say itโ€™s a breakdown in trust
www.nature.com/articles/d41...

28.09.2025 18:39 โ€” ๐Ÿ‘ 2    ๐Ÿ” 1    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review

Appropriately critical commentary on cochrane reviews as the apply to matched targeted therapy by @viveksubbiah.bsky.social Journal of Clinical Oncology ascopubs.org/doi/full/10....

22.09.2025 21:17 โ€” ๐Ÿ‘ 2    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

PFS benefit noted with adagrasib

12.08.2025 02:40 โ€” ๐Ÿ‘ 3    ๐Ÿ” 1    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
10 Must-Read Posts in Immuno-Oncology This Week - OncoDaily 10 Must-Read Posts in Immuno-Oncology This Week / Alex Menzies, Alexander Van Akkooi, AndrewFurness, cancer, chemoimmunotherapy, Christian Blank, David

10 Must-Read Posts in Immuno-Oncology This Week

@viveksubbiah.bsky.social @jiajennyliu.bsky.social @gerryhanna.bsky.social @drjnaidoo.bsky.social

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #IO #ImmuneOncology

24.08.2025 21:58 โ€” ๐Ÿ‘ 10    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma - OncoDaily Vivek Subbiah: Nature Medicine Study on Molecular Profiling in Meningioma / Alexander P. Landry, Andrew Ajisebutu, cancer, Chloe Gui, Farshad Nassiri, Gelareh

Nature Medicine Study on Molecular Profiling in Meningioma - @viveksubbiah.bsky.social

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine

04.09.2025 01:31 โ€” ๐Ÿ‘ 6    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too - OncoDaily Vivek Subbiah: Rare Cancers Deserve Breakthroughs Too / American Society of Clinical Oncology, ASCO, cancer, Conquer Cancer, Conquer Cancer the ASCO

Rare Cancers Deserve Breakthroughs Too - Vivek Subbiah

@viveksubbiah.bsky.social @conquercancer.bsky.social

oncodaily.com/blog/rare-ca...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

13.09.2025 14:15 โ€” ๐Ÿ‘ 4    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Top Articles Suggested by Vivek Subbiah - OncoDaily Top Articles Suggested by Vivek Subbiah / cancer, Nature, NEJM, OncoDaily, Oncology, Vivek Subbiah

Top Articles Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

14.09.2025 13:20 โ€” ๐Ÿ‘ 3    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer Interview with Jiyoung Ahn, PhD, author of Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer. Hosted by Vivek Subbiah, MD.

๐Ÿ”Š Listen to Jiyoung Ahn, PhD, of New York University, discuss with @viveksubbiah.bsky.social, MD, about whether the oral bacterial and fungal microbiome is associated with the development of pancreatic #cancer.

Listen now: ja.ma/41Vzuh9

18.09.2025 16:15 โ€” ๐Ÿ‘ 1    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - OncoDaily Vivek Subbiah: Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center / cancer, Fred Hutchย Cancer Center, OncoDaily,

Congratulations to Petros Grivas on Being Named Medical Director of Fred Hutch Cancer Center - Vivek Subbiah

@viveksubbiah.bsky.social @fredhutch.org

oncodaily.com/career/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

21.09.2025 18:17 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Top 5 Articles of the Week Suggested by Vivek Subbiah - OncoDaily Top 5 Articles of the Week Suggested by Vivek Subbiah / cancer, Cancer Discovery, Nature, OncoDaily, Oncology, Sarah Cannon Research Institute, Vivek Subbiah

Top 5 Articles of the Week Suggested by Vivek Subbiah

@viveksubbiah.bsky.social

oncodaily.com/voices/vivek...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

21.09.2025 18:18 โ€” ๐Ÿ‘ 5    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial Adagrasib demonstrated a statistically significant improvement in progression-free survival over docetaxel in patients with previously treated KRASG12C-mutated NSCLC, without new safety signals.

Adagrasib versus docetaxel in KRASG12C-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial - The Lancet www.thelancet.com/journals/lan...

11.08.2025 11:51 โ€” ๐Ÿ‘ 5    ๐Ÿ” 2    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 1
Preview
Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study Within hypermutated colorectal cancer, younger patients exhibited a higher mutational burden than older patients. Our study reveals an abnormal accumulation of distinct somatic mutations in hypermutat...

Patterns in genomic mutations among patients with early-onset colorectal cancer: an international, multicohort, observational study - The Lancet Oncology www.thelancet.com/journals/lan...

11.08.2025 11:49 โ€” ๐Ÿ‘ 5    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol We did not find significant evidence of an overall survival benefit of adding metformin to standard of care in the overall population of patients with metastatic hormone-sensitive prostate cancer. The...

Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol - The Lancet Oncology www.thelancet.com/journals/lan...

11.08.2025 11:49 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: We Donโ€™t Just Write What We Know, We Write to Discover What We Could Know - OncoDaily Vivek Subbiah: We Donโ€™t Just Write What We Know, We Write to Discover What We Could Know / cancer, Nature Reviews Bioengineering, OncoDaily, Oncology, Vivek

What is Missing to Fully Harness Precision Medicine and Transform Cancer Care - Vivek Subbiah
@viveksubbiah.bsky.social
@natmed.nature.com

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #PrecisionMedicine

21.07.2025 22:54 โ€” ๐Ÿ‘ 5    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Itโ€™s Time We Evolve WHO Cancer Classification - OncoDaily Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: โ€œHappy 4th everyone! Delighted to share with the our comment just published in t...

Itโ€™s Time We Evolve WHO Cancer Classification - Vivek Subbiah
@viveksubbiah.bsky.social
@who.int

oncodaily.com/science/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #CancerClassification #WHO

07.07.2025 19:14 โ€” ๐Ÿ‘ 8    ๐Ÿ” 2    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options - OncoDaily Vivek Subbiah: How Clinical Trials Offer Hope for Those Facing Limited Options / cancer, OncoDaily, Oncology, Sarah Cannon Research Institute, Sarcoma

How Clinical Trials Offer Hope for Those Facing Limited Options - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/clinica...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrial #Sarcoma #SarcomaAwarenessMonth

05.07.2025 23:02 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.โ€™s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

โญ๏ธTissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

29.05.2025 15:26 โ€” ๐Ÿ‘ 15    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 1
Post image

๐Ÿšจ Hot off the press! ๐Ÿšจ The @myesmo.bsky.social ESMO Precision Oncology Working Group, has unveiled key "Recommendations for structuring Molecular Tumour Boards (MTBs) in clinical practice", now published in ESMO's flagship journal Annals of Oncology ๐Ÿงฌ๐Ÿฅ
www.annalsofoncology.org/article/S092...

08.04.2025 02:16 โ€” ๐Ÿ‘ 10    ๐Ÿ” 3    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Cancer Isnโ€™t Just a Human Disease - Itโ€™s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - OncoDaily Vivek Subbiah: Cancer Isnโ€™t Just a Human Disease - Itโ€™s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs / Amy M. Boddy,

Cancer Isnโ€™t Just a Human Disease โ€“ Itโ€™s a Biological Reality Across Species, From Dogs to Tigers to the Extinct Dinosaurs - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/vivek-s...

#OncoDaily #Oncology #Cancer #Medicine #Health

22.06.2025 17:21 โ€” ๐Ÿ‘ 5    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
25 Posts Not to Miss from EHA 2025: - OncoDaily The European Hematology Association (EHA 2025) congress is officially underway in Milan. From June 12 to 15, hematology professionals from

25 Posts Not to Miss from EHA 2025
@nicogagelmann.bsky.social @talhabadarmd.bsky.social @majorajay.bsky.social @vincentrk.bsky.social @viveksubbiah.bsky.social @nejm.org

oncodaily.com/societies/eh...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #EHA2025 #EHA25

17.06.2025 14:21 โ€” ๐Ÿ‘ 9    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? - OncoDaily Vivek Subbiah: Why Every Rare Cancer Patient Deserves Molecular Profiling? / Bettina Ryll, Branko Cuglievan, cancer, clinical trials, FDA, Howard A. Burris

Why Every Rare Cancer Patient Deserves Molecular Profiling? - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/insight/vive...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #RareCancers #MolecularProfiling

15.06.2025 19:22 โ€” ๐Ÿ‘ 15    ๐Ÿ” 4    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

Super interesting.

"Tissue-agnostic #cancer therapies promise 2 revolutionize oncology by targeting molecular drivers. [A] study of nearly 300K tumors found 21.5% w/tissue-agnostic indications. Despite 9 #FDA approvals, real-world implementation challenges ..." 1/2 #CanSky #OncSky #ASCO25

29.05.2025 15:30 โ€” ๐Ÿ‘ 4    ๐Ÿ” 1    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Tissue-agnostic cancer therapies: promise, reality, and the path forward - Nature Communications Tissue-agnostic cancer therapies promise to revolutionize oncology by targeting molecular drivers. Sledge et al.โ€™s study of nearly 300,000 tumors found 21.5% with tissue-agnostic indications. Despite ...

โญ๏ธTissue-agnostic cancer therapies: promise, reality, and the path forward
@natcomms.nature.com @ascocancer.bsky.social #ASCO25
www.nature.com/articles/s41...

29.05.2025 15:26 โ€” ๐Ÿ‘ 15    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 1
Preview
ASCO and Google create โ€˜walled gardenโ€™ AI tool for doctors to query groupโ€™s guidelines ASCO and Google Cloud's AI tool is meant to help oncologists query just its trusted cancer treatment guidelines, without extraneous information.

ASCO and Google create โ€˜walled gardenโ€™ AI tool for doctors to query groupโ€™s guidelines www.statnews.com/2025/05/21/a... via @statnews.com

22.05.2025 00:59 โ€” ๐Ÿ‘ 4    ๐Ÿ” 3    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - OncoDaily Vivek Subbiah: Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer / ASCO25, cancer, fight against cancer, Global fight

Honored to Work Alongside an Incredible Team of Investigators Dedicated to Ending Cancer - Vivek Subbiah
@viveksubbiah.bsky.social

oncodaily.com/blog/team-of...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #ClinicalTrialsDay #ASCO25

21.05.2025 18:33 โ€” ๐Ÿ‘ 7    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Preview
Inspiring Journey of the 2024 Yvonne Awardees โ€” A Year of Impact and Leadership - OncoDaily Inspiring Journey of the 2024 Yvonne Awardees โ€” A Year of Impact and Leadership / Africa oncology, Asia cancer research, CAN-PIVOT project, cancer, cancer

Inspiring Journey of the 2024 Yvonne Awardees - A Year of Impact and Leadership
@drasyaagulnik.bsky.social
@viveksubbiah.bsky.social

oncodaily.com/blog/yvonne-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Yvonne #Leadership

17.05.2025 14:32 โ€” ๐Ÿ‘ 7    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0
Post image

โญ๏ธTo all the incredible moms who fill our lives with love, strength, and wisdom-today is for you.
๐Ÿ™๐ŸฝThank you for being the heart of every home & the foundation of so many dreams. Happy Motherโ€™s Day! ๐Ÿ’โค๏ธ #MothersDay

11.05.2025 16:03 โ€” ๐Ÿ‘ 3    ๐Ÿ” 0    ๐Ÿ’ฌ 1    ๐Ÿ“Œ 0
Preview
Vivek Subbiah: Exhilarating discussions on new podcast - Immunoverse - OncoDaily Vivek Subbiah: Exhilarating discussions on new podcast - Immunoverse / Aung Naing, cancer, fight against cancer, Global fight against cancer, ImmunoVerse,

Exhilarating discussions on new podcast: Immunoverse - Vivek Subbiah

@viveksubbiah.bsky.social @patrickhwumd.bsky.social @moffittnews.bsky.social

oncodaily.com/blog/immunov...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Immunoverse #Podcast

28.04.2025 19:04 โ€” ๐Ÿ‘ 9    ๐Ÿ” 1    ๐Ÿ’ฌ 0    ๐Ÿ“Œ 0

@viveksubbiah is following 20 prominent accounts